Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has received an average recommendation of “Buy” from the ten ratings firms that are currently covering the company, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $46.43.

DNTH has been the subject of a number of analyst reports. Oppenheimer boosted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Raymond James lifted their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Finally, Wedbush dropped their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently modified their holdings of DNTH. Barclays PLC grew its holdings in shares of Dianthus Therapeutics by 390.5% during the 3rd quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after purchasing an additional 33,185 shares during the period. Jane Street Group LLC purchased a new stake in Dianthus Therapeutics during the third quarter worth approximately $556,000. Wellington Management Group LLP acquired a new stake in shares of Dianthus Therapeutics in the third quarter worth $1,473,000. State Street Corp raised its stake in shares of Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Dianthus Therapeutics by 151.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after acquiring an additional 263,500 shares in the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $23.99 on Monday. Dianthus Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $33.77. The company has a market capitalization of $710.10 million, a price-to-earnings ratio of -9.60 and a beta of 1.84. The stock has a fifty day moving average of $26.66 and a two-hundred day moving average of $26.54.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The company had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. On average, analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.